Search Results - "Gloria Huang"

IGF2 signaling and regulation in cancer by Brouwer-Visser, Jurriaan, Huang, Gloria S

“…Abstract Upregulation of IGF2 occurs in both childhood and adult malignancies. Its overexpresssion is associated with resistance to chemotherapy and worse…”
Get full text

Precision Therapy for Aggressive Endometrial Cancer by Reactivation of Protein Phosphatase 2A by Haines, Kaitlin, Huang, Gloria S

“…Critically important to reducing uterine cancer mortality is the development of more effective therapy for aggressive endometrial cancers, including uterine…”
Get full text

An investigation of common crosslinking agents on the stability of electrospun collagen scaffolds by Huang, Gloria Portocarrero, Shanmugasundaram, Shobana, Masih, Pallavi, Pandya, Deep, Amara, Suwah, Collins, George, Arinzeh, Treena Livingston

“…Electrospinning is a widely used processing method to form fibrous tissue engineering scaffolds that mimic the structural features of the native extracellular…”
Get full text

ARID1A in Gynecologic Precancers and Cancers by Morgan, Jaida E, Jaferi, Nishah, Shonibare, Zainab, Huang, Gloria S

“…The highest frequency of genetic alterations in the tumor suppressor ARID1A occurs in malignancies of the female reproductive tract. The prevalence of ARID1A…”
Get more information

L‐4‐thiazolylalanine (Protinol), a novel non‐proteinogenic amino acid, demonstrates epidermal and dermal efficacy with clinically observable benefits by Portocarrero Huang, Gloria, Idkowiak‐Baldys, Jolanta, Liebel, Frank, Jones, Constantina, Haxaire, Coline, DiNatale, Lisa, Bayat, Ardeshir, Glynn, John R.

“…Objective Facial skin undergoes major structural and functional changes as a result of intrinsic and extrinsic factors. The goal of the current work is to…”
Get full text

Intersections of endocrine pathways and the epithelial mesenchymal transition in endometrial cancer by Gelissen, Julia H., Huang, Gloria S.

“…The epithelial mesenchymal transition (EMT) is the process by which cancer cells of epithelial origin, including endometrial cancer, acquire a mesenchymal…”
Get full text

Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy by Zammataro, Luca, Lopez, Salvatore, Bellone, Stefania, Pettinella, Francesca, Bonazzoli, Elena, Perrone, Emanuele, Zhao, Siming, Menderes, Gulden, Altwerger, Gary, Han, Chanhee, Zeybek, Burak, Bianchi, Anna, Manzano, Aranzazu, Manara, Paola, Cocco, Emiliano, Buza, Natalia, Hui, Pei, Wong, Serena, Ravaggi, Antonella, Bignotti, Eliana, Romani, Chiara, Todeschini, Paola, Zanotti, Laura, Odicino, Franco, Pecorelli, Sergio, Donzelli, Carla, Ardighieri, Laura, Angioli, Roberto, Raspagliesi, Francesco, Scambia, Giovanni, Choi, Jungmin, Dong, Weilai, Bilguvar, Kaya, Alexandrov, Ludmil B., Silasi, Dan-Arin, Huang, Gloria S., Ratner, Elena, Azodi, Masoud, Schwartz, Peter E., Pirazzoli, Valentina, Stiegler, Amy L., Boggon, Titus J., Lifton, Richard P., Schlessinger, Joseph, Santin, Alessandro D.

“…The prognosis of advanced/recurrent cervical cancer patients remains poor. We analyzed 54 fresh-frozen and 15 primary cervical cancer cell lines, along with…”
Get full text

Insulin-like growth factor 2 silencing restores taxol sensitivity in drug resistant ovarian cancer by Brouwer-Visser, Jurriaan, Lee, Jiyeon, McCullagh, KellyAnne, Cossio, Maria J, Wang, Yanhua, Huang, Gloria S

“…Drug resistance is an obstacle to the effective treatment of ovarian cancer. We and others have shown that the insulin-like growth factor (IGF) signaling…”
Get full text

Scattered Islands by Huang, Gloria L

Get full text

Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors by Li, Charles, Bonazzoli, Elena, Bellone, Stefania, Choi, Jungmin, Dong, Weilai, Menderes, Gulden, Altwerger, Gary, Han, Chanhee, Manzano, Aranzazu, Bianchi, Anna, Pettinella, Francesca, Manara, Paola, Lopez, Salvatore, Yadav, Ghanshyam, Riccio, Francesco, Zammataro, Luca, Zeybek, Burak, Yang-Hartwich, Yang, Buza, Natalia, Hui, Pei, Wong, Serena, Ravaggi, Antonella, Bignotti, Eliana, Romani, Chiara, Todeschini, Paola, Zanotti, Laura, Zizioli, Valentina, Odicino, Franco, Pecorelli, Sergio, Ardighieri, Laura, Silasi, Dan-Arin, Litkouhi, Babak, Ratner, Elena, Azodi, Masoud, Huang, Gloria S, Schwartz, Peter E, Lifton, Richard P, Schlessinger, Joseph, Santin, Alessandro D

“…Ovarian cancer remains the most lethal gynecologic malignancy. We analyzed the mutational landscape of 64 primary, 41 metastatic, and 17 recurrent fresh-frozen…”
Get full text

Integrated mutational landscape analysis of uterine leiomyosarcomas by Choi, Jungmin, Manzano, Aranzazu, Dong, Weilai, Bellone, Stefania, Bonazzoli, Elena, Zammataro, Luca, Yao, Xiaotong, Deshpande, Aditya, Zaidi, Samir, Guglielmi, Adele, Gnutti, Barbara, Nagarkatti, Nupur, Tymon-Rosario, Joan R., Harold, Justin, Mauricio, Dennis, Zeybek, Burak, Menderes, Gulden, Altwerger, Gary, Jeong, Kyungjo, Zhao, Siming, Buza, Natalia, Hui, Pei, Ravaggi, Antonella, Bignotti, Eliana, Romani, Chiara, Todeschini, Paola, Zanotti, Laura, Odicino, Franco, Pecorelli, Sergio, Ardighieri, Laura, Bilguvar, Kaya, Quick, Charles M., Silasi, Dan-Arin, Huang, Gloria S., Andikyan, Vaagn, Clark, Mitchell, Ratner, Elena, Azodi, Masoud, Imielinski, Marcin, Schwartz, Peter E., Alexandrov, Ludmil B., Lifton, Richard P., Schlessinger, Joseph, Santin, Alessandro D.

“…Uterine leiomyosarcomas (uLMS) are aggressive tumors arising from the smooth muscle layer of the uterus. We analyzed 83 uLMS sample genetics, including 56 from…”
Get full text

Antidepressants normalize elevated Toll-like receptor profile in major depressive disorder by Hung, Yi-Yung, Huang, Kai-Wei, Kang, Hong-Yo, Huang, Gloria Ya-Ling, Huang, Tiao-Lai

“…Rationale Abnormalities in Toll-like receptor (TLR) expression in depression have been inferred in part from observed increases in TLR4 levels in peripheral…”
Get full text

Designing a broad-spectrum integrative approach for cancer prevention and treatment by Block, Keith I, Gyllenhaal, Charlotte, Lowe, Leroy, Amedei, Amedeo, Amin, Amr, Aquilano, Katia, Arreola, Alexandra, Azmi, Asfar S, Bilsland, Alan, Block, Penny B, Boosani, Chandra S, Carey, Thomas E, Carnero, Amancio, Chakrabarti, Mrinmay, Chaturvedi, Rupesh, Chen, Sophie, Chen, Yi Charlie, Choi, Beom K, Ciriolo, Maria Rosa, Coley, Helen M, Collins, Andrew R, Connell, Marisa, Crawford, Sarah, Dabrosin, Charlotta, Damia, Giovanna, Dong, Jin-Tang, Elkord, Eyad, Ferguson, Lynnette R, Fimognari, Carmela, Firestone, Gary L, Fujii, Hiromasa, Fuster, Mark M, Gieseler, Frank, Gilbertson, Michael, Grue, Brendan, Guha, Gunjan, Halicka, Dorota, Helferich, William G, Hentosh, Patricia, Hsu, Hsue-Yin, Huang, Gloria S, Jones, Lee W, Khatami, Mahin, Ko, Young H, Kucuk, Omer, Kulathinal, Rob J, Kumar, Nagi B, Kwon, Byoung S, Lea, Michael A, Lee, Ho-Young, Lin, Liang-Tzung, Locasale, Jason W, Lokeshwar, Bal L, Longo, Valter D, MacKenzie, Karen L, Malhotra, Meenakshi, Marino, Maria, Matheu, Ander, Maxwell, Christopher, Mehrmohamadi, Mahya, Mehta, Kapil, Michelotti, Gregory A, Mohammed, Sulma I, Morre, D. James, Muqbil, Irfana, Niccolai, Elena, Pantano, Francesco, Pedersen, Peter L, Poudyal, Deepak, Prakash, Satya, Rathmell, Jeffrey C, Rathmell, W. Kimryn, Ray, Swapan K, Rezazadeh, Sarallah, Ribatti, Domenico, Rodier, Francis, Rupasinghe, H.P. Vasantha, Russo, Gian Luigi, Ryan, Elizabeth P, Santini, Daniele, Sarkar, Malancha, Sasada, Tetsuro, Shackelford, Rodney E, Shin, Dong M, Sidransky, David, Siegelin, Markus David, Sliva, Daniel, Stafforini, Diana M, Stagg, John, Talib, Wamidh H, Vander Heiden, Matthew G, Vlachostergios, Panagiotis J, Wang, Zongwei, Wellen, Kathryn E, Yang, Eddy S, Yang, Huanjie, Yang, Xujuan, Yaswen, Paul, Yedjou, Clement, Zhu, Jiyue

“…Abstract Targeted therapies and the consequent adoption of “personalized” oncology have achieved notable successes in some cancers; however, significant…”
Get full text

RNA-seq Identification of RACGAP1 as a Metastatic Driver in Uterine Carcinosarcoma by Mi, Shijun, Lin, Mingyan, Brouwer-Visser, Jurriaan, Heim, Jennifer, Smotkin, David, Hebert, Tiffany, Gunter, Marc J, Goldberg, Gary L, Zheng, Deyou, Huang, Gloria S

“…Uterine carcinosarcoma is a rare aggressive malignancy frequently presenting at advanced stage of disease with extrauterine metastases. Median survival is less…”
Get full text

Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression by Mauricio, Dennis, Bellone, Stefania, Mutlu, Levent, McNamara, Blair, Manavella, Diego D., Demirkiran, Cem, Verzosa, Miguel Skyler Z., Buza, Natalia, Hui, Pei, Hartwich, Tobias Max Philipp, Harold, Justin, Yang-Hartwich, Yang, Zipponi, Margherita, Altwerger, Gary, Ratner, Elena, Huang, Gloria S., Clark, Mitchell, Andikyan, Vaagn, Azodi, Masoud, Schwartz, Peter E., Santin, Alessandro D.

“…Carcinosarcomas are highly aggressive gynecologic malignancies containing both carcinomatous and sarcomatous elements with heterogeneous HER2/neu expression…”
Get full text

Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma by Harold, Justin, Bellone, Stefania, Manavella, Diego D., Mutlu, Levent, McNamara, Blair, Hartwich, Tobias Max Philipp, Zipponi, Margherita, Yang-Hartwich, Yang, Demirkiran, Cem, Verzosa, Miguel Skyler, Choi, Jungmin, Dong, Weilai, Buza, Natalia, Hui, Pei, Altwerger, Gary, Huang, Gloria S., Andikyan, Vaagn, Clark, Mitchell, Ratner, Elena, Azodi, Masoud, Schwartz, Peter E., Santin, Alessandro D.

“…Uterine leiomyosarcoma (uLMS) is a rare, highly aggressive malignancy. Recent data suggest 50% of uLMS may harbor alterations in the ATRX gene and such…”
Get full text

A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability by Bellone, Stefania, Roque, Dana M., Siegel, Eric R., Buza, Natalia, Hui, Pei, Bonazzoli, Elena, Guglielmi, Adele, Zammataro, Luca, Nagarkatti, Nupur, Zaidi, Samir, Lee, Jungsoo, Silasi, Dan‐Arin, Huang, Gloria S., Andikyan, Vaagn, Damast, Shari, Clark, Mitchell, Azodi, Masoud, Schwartz, Peter E., Tymon‐Rosario, Joan R., Harold, Justin A., Mauricio, Dennis, Zeybek, Burak, Menderes, Gulden, Altwerger, Gary, Ratner, Elena, Alexandrov, Ludmil B., Iwasaki, Akiko, Kong, Yong, Song, Eric, Dong, Weilai, Elvin, Julia A., Choi, Jungmin, Santin, Alessandro D.

“…Background Microsatellite instability–high (MSI‐H)/mismatch repair deficiency (dMMR) is a biomarker for responses to immune checkpoint inhibitors (ICIs)…”
Get full text

A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma by Han, Chanhee, Bellone, Stefania, Siegel, Eric R., Altwerger, Gary, Menderes, Gulden, Bonazzoli, Elena, Egawa-Takata, Tomomi, Pettinella, Francesca, Bianchi, Anna, Riccio, Francesco, Zammataro, Luca, Yadav, Ghanshyam, Marto, Jarrod A., Penet, Marie-France, Levine, Douglas A., Drapkin, Ronny, Patel, Abhijit, Litkouhi, Babak, Ratner, Elena, Silasi, Dan-Arin, Huang, Gloria S., Azodi, Masoud, Schwartz, Peter E., Santin, Alessandro D.

“…Since the majority of patients are diagnosed at an advanced stage, ovarian cancer remains the most lethal gynecologic malignancy. There is no single biomarker…”
Get full text

Genetic landscape of clear cell endometrial cancer and the era of precision medicine by Huang, Gloria S., Santin, Alessandro D.

“…The increased understanding of the genetic landscape of clear cell endometrial cancer should guide the development of precision medicine strategies to improve…”
Get full text

Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu by Tymon-Rosario, Joan, Siegel, Eric R., Bellone, Stefania, Harold, Justin, Adjei, Naomi, Zeybek, Burak, Mauricio, Dennis, Altwerger, Gary, Menderes, Gulden, Ratner, Elena, Clark, Mitchell, Andikyan, Vaagn, Huang, Gloria S., Azodi, Masoud, Schwartz, Peter E., Fader, Amanda N., Santin, Alessandro D.

“…Due to previously reported trastuzumab safety concerns and the scant data available in endometrial cancer patients, we sought to assess the safety,…”
Get full text